Jane R. Engler
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments, Cancer, Hypoxia, and Metabolism, Eosinophilic Disorders and Syndromes, Glioma Diagnosis and Treatment
Most-Cited Works
- → OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib(2006)431 cited
- → Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity(2007)330 cited
- → Proteoglycans and their roles in brain cancer(2013)192 cited
- → Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib(2010)182 cited
- → Increased Microglia/Macrophage Gene Expression in a Subset of Adult and Pediatric Astrocytomas(2012)165 cited
- → GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity(2016)42 cited
- → Heparan Sulfate Glycosaminoglycans in Glioblastoma Promote Tumor Invasion(2017)36 cited
- → The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells(2010)23 cited
- → Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM(2019)22 cited
- → Measuring Sulfatase Expression and Invasion in Glioblastoma(2014)12 cited